Automated Insulin Delivery System Tested in Adults With Type 2 Diabetes

Trial details

Who runs it

University of Cambridge

Trial code

NCT06579404

Record updated

13 March 2026

Original description

The main objective of this study is to determine the efficacy, safety and utility of fully closed-loop glucose control in the home setting in adults with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop systems that have been performed in Cambridge in adults with type 2 diabetes in the inpatient and in the home setting and in children and adults with type 1 diabetes.Read full original descriptionShow less

An Open-label, Multinational, Multicentre, Randomised, Single-period Parallel Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery Compared to Standard Insulin Therapy With CGM in Adults With Type 2 Diabetes

The main objective of this study is to determine the efficacy, safety and utility of fully closed-loop glucose control in the home setting in adults with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop systems that have been performed in Cambridge in adults with type 2 diabetes in the inpatient and in the home setting and in children and adults with type 1 diabetes.

This is an open-label, multi-national, multi-centre, randomised, single-period parallel study, involving a run-in period followed by a 26-week intervention period during which glucose levels will be controlled either by a fully closed-loop system or by participants usual insulin therapy with continuous glucose monitoring. A total of up to 224 adults with type 2 diabetes using insulin will be recruited through outpatient diabetes clinics, primary care centres, social media advertising and other established methods at participating centres. Participants will receive appropriate training in the safe use of the study devices.

The primary outcome is the between group difference in HbA1c at 26 weeks. Other key outcomes include the time spent with glucose levels within, above and below the target glucose range (3.9-10.0mmol/L) and mean sensor glucose as recorded by CGM over the 26 weeks. Insulin requirements, body weight, renal and liver function will also be compared. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Human factors outcomes include CGM \& closed-loop usage, questionnaires and semi-structured interviews.

Inclusion: Aged 18 years and older; Type 2 diabetes diagnosed for at least 12 months; Established on an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, or have been offered these therapies previously; Treatment with insulin therapy for at least 6 months; HbA1c ≤ 15% (140 mmol/mol) analysis from local laboratory or equivalent; Willing to wear study devices and follow study instructions; Capacity to consent to participate in the study.

Exclusion: Illicit drugs abuse; Prescription drugs abuse; Type 1 diabetes; Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician; Known or suspected allergy against insulin; Medically documented allergy towards the adhesive; Severe visual impairment; Severe hearing impairment; Medically documented allergy towards the adhesive (glue) of plasters; Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor; Current use of insulin pump; Current use of any closed-loop system; Pregnancy, planned pregnancy, or breast feeding; Alcohol abuse.

ClinicalTrials.gov NCT06579404